AEs |
adverse events |
AE-QoL |
angioedema quality of life questionnaire |
BTK |
Bruton’s tyrosine kinase |
CI |
confidence interval |
CRS |
chronic rhinosinusitis |
CU |
chronic urticaria |
CU-Q2oL |
chronic urticaria quality of life questionnaire |
CSU |
chronic spontaneous urticaria |
FDA |
Food and Drug Administration |
EMA |
European Medicine Agency |
FcεRI |
high affinity IgE receptor |
DLQI |
dermatology life quality index |
H1AH |
H1 antihistamines |
H2AH |
H2 antihistamines |
HRQoL |
health-related quality of life |
HSS7 |
weekly hives severity score |
IgE |
immunoglobulin E |
IgG |
immunoglobulin G |
ISI |
insomnia severity index |
ISS7 |
weekly itch severity score |
LTRAs |
leukotriene receptor antagonists |
mAbs |
monoclonal antibodies |
OR |
odds ratio |
RDBPCT |
randomized double-blind placebo controlled trial |
RCTs |
randomized controlled trials |
SAEs |
serious adverse events |
TPO |
thyroperoxidase |
TSLP |
anti-thymic stromal lymphopoietin |
UAS7 |
weekly urticaria activity score |
Versus |
vs. |
WPAI |
work productivity and activity impairment |